“The actions outlined today will better position us to drive meaningful earnings growth and further strengthen the company to ...

Detailed price information for Charles River Laboratories Intl (CRL-N) from The Globe and Mail including charting and trades.

Detailed price information for Charles River Laboratories Intl (CRL-N) from The Globe and Mail including charting and trades.

Despite a slight revenue decline, CRL focuses on strategic initiatives and cost savings to drive long-term growth and ...

Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast after posting strong third-quarter results, helped by stabilized demand for its drug discovery and ...

Charles River Laboratories Intl (($CRL)) has held its Q3 earnings call. Read on for the main highlights of the call. The ...

PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio, Inc. and Charles River Laboratories, Inc. have announced a strategic alliance to offer complementary services to clients including early development and ...

Charles River Laboratories International, Inc. (NYSE: CRL) has joined the EASYGEN (Easy Workflow Integration for Gene Therapy) Consortium, a European Union (EU)-backed effort to produce CAR-T cell ...

Conduit Pharmaceuticals partners with Charles River to evaluate AZD1656 for lupus, enhancing preclinical research and improving Phase II trial success. Conduit Pharmaceuticals has announced a ...

To the dismay of advocates and residents, the Massachusetts Water Resource Authority proposed a plan at a Wednesday meeting ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Elly’s Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with ...